1
|
Ikarashi A, Murakami Y, Toshiyasu T, Yoshioka M, Kamima T, Tokumasu K, Nakano M, Hashimoto T, Oguchi M, Yoshioka Y. Prediction of Late Xerostomia after Radiotherapy by Integrating Dosiomics and Conventional Predictive Factors in Patients With Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Murakami Y, Murakami Y, Kamima T, Abo N, Takahashi T, Kaneko M, Nakano M, Matsubayashi F, Harada A, Taguchi S, Hashimoto T, Oguchi M, Yoshioka Y. Dosimetric Comparison Between 3D Conformal Radiation Therapy Plus Electron Boost and Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Left-Sided Breast Cancer Patients With a Potential Risk of Radiation-Induced Cardiac Toxicity. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Miyauchi H, Tanaka Y, Takahashi K, Nakano M, Hasegawa T, Hashimoto M, Hashimoto T, Oguchi M, Yoshioka Y. Development of Novel Image Processing System Using Super-Resolution to Reduce Cone-Beam CT Imaging Dose in Radiation Therapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Murakami Y, Soyano T, Kozuka T, Ushijima M, Koizumi Y, Miyauchi H, Kaneko M, Nakano M, Kamima T, Hashimoto T, Oguchi M, Yoshioka Y. Can Dosiomics Features Be Relevant Predictive Factors for Biochemical Recurrence After Radiotherapy in Prostate Cancer Patients? Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Ito M, Takase Y, Sasamura K, Kotsuma T, Ooshima Y, Minami Y, Suzuki J, Tanaka E, Oguchi M, Okuda T, Suzuki K, Yoshioka Y. Comparison of Physician-Recorded Toxicities and Patient-Reported Outcomes Among 5 Different Radiotherapy Methods for Prostate Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Yoshikawa T, Haruki N, Yoshimura C, Yoshioka Y, Ando SI. The relationships between hypoxia and oxidative stress as well as anti-oxidant activity in patients with severe sleep disordered breathing. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.1216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Yamashita T, Kamada H, Kanasaki S, Nagano K, Inoue M, Higashisaka K, Yoshioka Y, Tsutsumi Y, Tsunoda S. Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling. Pharmazie 2019; 74:614-619. [PMID: 31685088 DOI: 10.1691/ph.2019.9474] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Exosomes are potent players in the development of metastases and they play an important role in cancer angiogenesis and exacerbation. However, it is unclear how proteins on exosomes affect development of blood vessel networks. In this study, we focused on relationships between membrane proteins on exosomes and angiogenesis using human umbilical vein endothelial cells (HUVEC). Lung tumor cell-derived exosomes induced tube formation and growth of endothelial cells in vitro in a dose-dependent manner involving MAPK activation, but this was not seen in normal lung epithelial cells. Ephrin type-A receptor 2 (EphA2) was identified by proteomic analysis and an inhibition assays showed it is a major MAPK activator on exosomes. Thus EphA2 on exosomes participates in angiogenesis as a ligand of the ephrin signaling pathway. These results support the development of novel therapeutic strategies such as blockade of remote cancer communications through exosomes.
Collapse
|
8
|
Taguchi S, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Takeuchi K, Terui Y, Oguchi M. Assessment of Late Toxicities of Liver and Kidney after Definitive Radiotherapy for Gastric MALT Lymphoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Yoshioka Y, Hayashi S, Hamada A, Toratani S, Okamoto T. Metastasis of carcinoma ex pleomorphic adenoma to the brain without previous metastasis to the lungs or bones: a case report. Br J Oral Maxillofac Surg 2019; 57:926-928. [PMID: 31405601 DOI: 10.1016/j.bjoms.2019.07.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 07/19/2019] [Indexed: 11/18/2022]
Abstract
Carcinoma ex pleomorphic adenoma is a rare type of cancer of the salivary gland that involves the malignant transformation of a primary or recurrent pleomorphic adenoma, which often metastasises to the lungs or bones, or both. To the best of our knowledge, however, nobody has reported a distant metastasis of this lesion to the brain without such previous metastasis. We report a case in a 64-year-old man.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University.
| | - S Hayashi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University
| | - A Hamada
- Oral and Maxillofacial Surgery, Hiroshima University Hospital
| | - S Toratani
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University
| | - T Okamoto
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Science, Graduate Institute of Biomedical and Health Science, Hiroshima University; Oral and Maxillofacial Surgery, Hiroshima University Hospital
| |
Collapse
|
10
|
Toratani S, Ogawa I, Sasahara H, Yoshioka Y, Kanda T, Tani R, Okamoto T. Pathological factors involved in local failure in squamous cell carcinoma of the oral cavity: retrospective study and proposal of a new clinical classification. Int J Oral Maxillofac Surg 2019; 48:143-151. [DOI: 10.1016/j.ijom.2018.07.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Revised: 04/03/2018] [Accepted: 07/06/2018] [Indexed: 01/28/2023]
|
11
|
Harada A, Sumi M, Toshiyasu T, Yoshioka Y, Takazawa Y, Ae K, Matsumoto S, Oguchi M. Palliative Radiation Therapy for Spinal Metastasis from Myxoid Liposarcoma. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Isoda K, Daibo T, Yushina K, Yoshioka Y, Tsutsumi Y, Akimoto Y, Kawakami H, Taira Y, Taira I, Yanoshita R, Nishimura T, Ishida I. Hepatotoxicity, nephrotoxicity, and drug/chemical interaction toxicity of platinum nanoparticles in mice. Pharmazie 2018; 72:10-16. [PMID: 29441891 DOI: 10.1691/ph.2017.6758] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Nanomaterials are frequently used in microelectronics, cosmetics, and sunscreens. Platinum reagents are commonly used in disease diagnosis, cosmetics, and the food industry. Although research into the development of nanomaterialbased drug delivery systems has yielded promising results, the toxicity of these materials is not fully understood. We investigated the toxicity and drug interactions of 1- and 8-nm diameter platinum nanoparticles (nPt1 and nPt8, respectively) in mice. Acute hepato-renal toxicity of intravenously administered platinum nanoparticles was evaluated biochemically and histologically. Dose-dependent increases in serum markers of hepato-renal function (serum aminotransferases and blood urea nitrogen) were observed following administration of nPt1, whereas nPt8 had no effect, even at 20 mg/kg. Moreover, nPt1 induced interleukin (IL)-6 and IL-1β production 3 and 6 hours after administration. The effect of nPts on drug-induced toxicity was evaluated in mice injected intraperitoneally with carbon tetrachloride or cisplatin, with or without intravenous administration of platinum nanoparticles. All treatments in the absence of nanoparticles were non-lethal and resulted in moderate toxicity. However, exacerbated toxicity was observed in mice injected with carbon tetrachloride or cisplatin together with nPt1, but not in mice co-injected with nPt8. We found that nPt1 cause hepato-renal damage, and the effect is enhanced by chemical inducers of hepatotoxicity and nephrotoxicity. This is the first report demonstrating that nPt1 not only are hepatotoxic and nephrotoxic but also exacerbate drug toxicity. These findings will be useful for future nanotechnology and nanoscience research.
Collapse
|
13
|
Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Nakatsuji K, Kobayashi Y, Fujii T, Iida S. Cathepsin K inhibitor causes changes in crystallinity and crystal structure of newly-formed mandibular bone in rats. Br J Oral Maxillofac Surg 2018; 56:732-738. [PMID: 30131193 DOI: 10.1016/j.bjoms.2018.08.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 08/03/2018] [Indexed: 11/16/2022]
Abstract
Cathepsin K inhibitors are new drugs with the potential for the treatment of osteoporosis because they sustain bony remodelling better than bone resorption inhibitors such as bisphosphonates. The treatment of osteoporosis with inhibitors of bony resorption is associated with osteonecrosis of the jaw, as the deterioration in bony quality that they induce is thought to be one of its causes. The quality of bone is delineated by structural and material characteristics (which include the degree and quality of mineralisation, and depends on the content of proteoglycan and the structural integrity of the bony collagen).1,2 Animal and clinical studies have shown that cathepsin K inhibitors improve the mineral density and structural characteristics of bone, but their effect on the rest remains unknown. We therefore hypothesised that these inhibitors will affect the material characteristics of newly-formed mandibular bone. To verify our hypothesis, we used Raman microspectroscopy to examine such bone in rats that were given a cathepsin K inhibitor, and found unusual crystallinity and an increased substitution of carbonate (CO32-) in its crystal structure.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| | - E Yamachika
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan.
| | - M Nakanishi
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 1-1-1 Tsushima-Naka, Kita-ku, Okayama City 700-8530, Japan
| | - T Ninomiya
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, 1780 Gobara Hirooka, Shiojiri, Nagano 399-0781, Japan
| | - K Nakatsuji
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| | - Y Kobayashi
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, 1780 Gobara Hirooka, Shiojiri, Nagano 399-0781, Japan
| | - T Fujii
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 1-1-1 Tsushima-Naka, Kita-ku, Okayama City 700-8530, Japan
| | - S Iida
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City 700-8558, Japan
| |
Collapse
|
14
|
Yoshioka Y, Yamachika E, Nakanishi M, Ninomiya T, Nakatsuji K, Matsubara M, Moritani N, Kobayashi Y, Fujii T, Iida S. Molecular alterations of newly formed mandibular bone caused by zoledronate. Int J Oral Maxillofac Surg 2018; 47:1206-1213. [PMID: 29550280 DOI: 10.1016/j.ijom.2018.02.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 12/07/2017] [Accepted: 02/06/2018] [Indexed: 12/21/2022]
Abstract
Bone quality is defined by structural and material characteristics. Most studies on the mandible have focused on the analysis of structural characteristics, with insufficient investigation of material characteristics. This study tested whether zoledronate affects the material characteristics of newly formed mandibular bone. Thirty-six female Wistar rats were assigned to three groups: sham-ovariectomized rats (SHAM, n=12), ovariectomized rats (OVX, n=12), and ovariectomized rats treated with zoledronate (ZOL, n=12). The left side of the mandibular ramus of all rats was drilled bicortically. Twenty-eight days after surgery, all surviving rats were euthanized and all mandibles were removed. Raman microspectroscopy was performed, and five spectra per specimen of newly formed mandibular bone were analysed. Compared with OVX rats, the mineral/matrix ratio in ZOL rats was significantly increased (5.43±1.88 vs. 7.86±2.05), while crystallinity (0.055±0.002 vs. 0.050±0.002), relative proteoglycan content (0.43±0.10 vs. 0.31±0.05), and collagen structural integrity (1.16±0.21 vs. 0.72±0.06) were significantly decreased. These changes in material characteristics may explain why rats that received zoledronate exhibited peculiar biological phenomena such as bisphosphonate-related osteonecrosis of the jaw.
Collapse
Affiliation(s)
- Y Yoshioka
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - E Yamachika
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Hospital, Okayama City, Japan.
| | - M Nakanishi
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, Okayama City, Japan
| | - T Ninomiya
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, Shiojiri, Nagano, Japan
| | - K Nakatsuji
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - M Matsubara
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - N Moritani
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| | - Y Kobayashi
- Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, Shiojiri, Nagano, Japan
| | - T Fujii
- Department of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, Okayama City, Japan
| | - S Iida
- Department of Oral and Maxillofacial Reconstructive Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Japan
| |
Collapse
|
15
|
Yoshioka Y, Yamamoto U, Tsuda H, Handa S, Yoshimura C, Tokunoh T, Nishizaka M, Ando SI. The factors that affect to the better compliance of mandibular advancement device when compared with continuous positive airway pressure in the patients with moderate to severe sleep apnea syndrome. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Murata K, Akiyama R, Noro I, Nishio A, Nakagawa S, Yoshioka Y, Deguchi T, Matsuda H, Ishida Y. Search for effective plant materials for Alzheimer's disease. Am J Transl Res 2017. [DOI: 10.1055/s-0037-1608412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- K Murata
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - R Akiyama
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - I Noro
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - A Nishio
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - S Nakagawa
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | | | - T Deguchi
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - H Matsuda
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| | - Y Ishida
- Faculty of Pharmacy, Kindai University, Higashiosaka, Japan
| |
Collapse
|
17
|
Fukuchi H, Okawa T, Yamamoto T, Kato S, Nakajima N, Yoshioka Y. Detection of recognition from ambiguous visual information using FMRI. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Amano M, Namiki T, Yoshioka Y, Arima Y, Kato K, Nojima K, Hanafusa T, Tokoro S, Miura K, Yokozeki H. Necrotizing fasciitis of the lower leg caused by Escherichia coli, and an association with pyogenic spondylitis. Clin Exp Dermatol 2017; 42:918-920. [PMID: 28925014 DOI: 10.1111/ced.13209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2017] [Indexed: 11/30/2022]
Affiliation(s)
- M Amano
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Namiki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - Y Yoshioka
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - Y Arima
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Kato
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Nojima
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - T Hanafusa
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - S Tokoro
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - K Miura
- Department of Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - H Yokozeki
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| |
Collapse
|
19
|
Moritani N, Yoshioka Y, Yamachika E, Matsui Y, Tabata M, Ikeda A, Uemura A, Nakatsuji K, Matsumura T, Iida S. A familial case of cleidocranial dysplasia with a frameshift mutation in the Runt-related transcription factor 2 gene. Int J Oral Maxillofac Surg 2017. [DOI: 10.1016/j.ijom.2017.02.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Kawashima A, Isohashi F, Mabuchi S, Okubo H, Tamari K, Seo Y, Suzuki O, Yoshioka Y, Kimura T, Ogawa K. Early Outcomes and Dose-Volume Analysis for Patients With Cervical Cancer Treated With Computed Tomography-Based Treatment Planning in Brachytherapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
21
|
Isohashi F, Mabuchi S, Yoshioka Y, Tamari K, Suzuki O, Koizumi M, Kawashima A, Okubo H, Kimura T, Ogawa K. Postoperative Whole-Pelvic Intensity Modulated Radiation Therapy in Surgically Treated Cervical Cancer Patients With Adverse Risk Factors. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Ono E, Murota H, Mori Y, Yoshioka Y, Katamaya I. 055 Metabolomics analysis of sweat derived from atopic dermatitis by use of nuclear magnetic resonance. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Hirai T, Yoshioka Y, Takahashi H, Handa T, Izumi N, Mori T, Uemura E, Nishijima N, Sagami K, Yamaguchi M, Eto S, Nagano K, Kamada H, Tsunoda S, Ishii KJ, Higashisaka K, Tsutsumi Y. High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis. Clin Exp Allergy 2016; 46:992-1003. [DOI: 10.1111/cea.12722] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Revised: 01/18/2016] [Accepted: 02/07/2016] [Indexed: 11/30/2022]
Affiliation(s)
- T. Hirai
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Yoshioka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
- BIKEN Center for Innovative Vaccine Research and Development; The Research Foundation for Microbial Diseases of Osaka University; Osaka Japan
| | - H. Takahashi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Vaccine Creation Project; BIKEN Innovative Vaccine Research Alliance Laboratories; Research Institute for Microbial Diseases; Osaka University; Osaka Japan
| | - T. Handa
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Izumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - T. Mori
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - E. Uemura
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - N. Nishijima
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Sagami
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - M. Yamaguchi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - S. Eto
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - K. Nagano
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
| | - H. Kamada
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - S. Tsunoda
- Laboratory of Biopharmaceutical Research; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| | - K. J. Ishii
- Laboratory of Adjuvant Innovation; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- Laboratory of Vaccine Science; Immunology Frontier Research Center; World Premier International Research Center; Osaka University; Osaka Japan
| | - K. Higashisaka
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
| | - Y. Tsutsumi
- Laboratory of Toxicology and Safety Science; Graduate School of Pharmaceutical Sciences; Osaka University; Osaka Japan
- Laboratory of Innovative Antibody Engineering and Design; Center for Drug Innovation and Screening; National Institutes of Biomedical Innovation; Health and Nutrition; Osaka Japan
- The Center for Advanced Medical Engineering and Informatics; Osaka University; Osaka Japan
| |
Collapse
|
24
|
Moritani N, Matsumura T, Yamachika E, Goda Y, Uemura A, Nakata N, Tamura S, Yoshioka Y, Iida S. A novel guide device of the osteotomy line for intraoral vertical ramus osteotomy. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Togashi Y, Yoshioka Y, Chikugo T, Terashima M, Mizukami T, Hayashi H, Sakai K, Velasco MD, Tomida S, Fujita Y, Okuno K, Nishio K. 2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31089-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Tsukasaki Y, Komatsuzaki A, Mori Y, Ma Q, Yoshioka Y, Jin T. A short-wavelength infrared emitting multimodal probe for non-invasive visualization of phagocyte cell migration in living mice. Chem Commun (Camb) 2015; 50:14356-9. [PMID: 25296382 DOI: 10.1039/c4cc06542e] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
For the non-invasive visualization of cell migration in deep tissues, we synthesized a short-wavelength infrared (SWIR) emitting multimodal probe that contains PbS/CdS quantum dots, rhodamine 6G and iron oxide nanoparticles. This probe enables multimodal (SWIR fluorescence/magnetic resonance) imaging of phagocyte cell migration in living mice.
Collapse
Affiliation(s)
- Y Tsukasaki
- RIKEN Quantitative Biology Center, 6-2-3 Furuedai, Suita, Osaka 565-0874, Japan.
| | | | | | | | | | | |
Collapse
|
27
|
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Asai S, Takahashi N, Funahashi K, Yoshioka Y, Takemoto T, Terabe K, Asai N, Ishiguro N, Kojima T. THU0078 Effects of Concomitant Methotrexate on the Long-Term Outcome of Knee Joint Destruction in Patients with Rheumatoid Arthritis Treated with Tumour Necrosis Factor Inhibitors. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Funahashi K, Kojima T, Takahashi N, Asai S, Yoshioka Y, Takemoto T, Terabe K, Asai N, Yabe Y, Ishiguro N. AB0466 The Outcome of Tocilizumab Treatment with Achievement of Glucocorticoids Withdrawal Against Rheumatoid Arthritis for 24 Months from TBC Registry. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Kojima T, Takahashi N, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Watanabe T, Hayashi M, Shioura T, Kanayama Y, Funahashi K, Asai S, Yoshioka Y, Terabe K, Takemoto T, Asai N, Ishiguro N. AB0485 Predictive Factors for Achievement of Low Disease Activity or Remission at 52 Weeks in Switching from TNF Inhibitors to Abatacept with Background of low Dose or no Methotrexate: A Multicenter Observational Cohort Study in Japan. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Kanayama Y, Hirano Y, Kaneko A, Takahashi N, Yoshioka Y, Kanda H, Hirabara S, Kojima T, Ishiguro N. THU0191 Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate: 52-Week Results – a Multicenter Registry Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Mizuno H, Mizuno H, Sumida I, Otani Y, Yagi M, Takashina M, Suzuki O, Yoshioka Y, Koizumi M, Ogawa K. SU-E-T-767: Treatment Planning Study of Prostate Cancer by CyberKnife with Respect to the Urethral Dose. Med Phys 2015. [DOI: 10.1118/1.4925131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
33
|
Asai N, Yabe Y, Kojima T, Takahashi N, Funahashi K, Asai S, Takemoto T, Terabe K, Yoshioka Y, Ishiguro N. AB0476 Influence of the Reason for Discontinuation of Previous TNF Antagonists on the Retention of Tocilizumab. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Shintani T, Hayashido Y, Mukasa H, Akagi E, Hoshino M, Ishida Y, Hamana T, Okamoto K, Kanda T, Koizumi K, Yoshioka Y, Tani R, Toratani S, Okamoto T. Comparison of the prognosis of bisphosphonate-related osteonecrosis of the jaw caused by oral and intravenous bisphosphonates. Int J Oral Maxillofac Surg 2015; 44:840-4. [PMID: 25861974 DOI: 10.1016/j.ijom.2015.03.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 03/13/2015] [Accepted: 03/23/2015] [Indexed: 01/03/2023]
Abstract
Bisphosphonates (BPs) have been used in medical practice for the treatment of osteoporosis, bone metastasis, and multiple myeloma. Although many studies have been published, the treatment and prognosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ) remain unclear. This study included 59 patients with BRONJ: 29 had taken oral BPs and 30 had taken intravenous (IV) BPs. All received conservative treatments. When separated sequestra were seen, a sequestrectomy was performed. Segmental mandibular resection was performed when pathological fractures were diagnosed. The outcomes of treatments were compared between groups. For patients treated with oral rinses or mandibular resection, the number in whom clinical healing was observed did not differ between the oral BP and IV BP groups. With regard to sequestrectomy, 94% of patients in the oral BP group showed improvement with this treatment compared to 50% in the IV BP group. The number of patients in whom clinical healing of BRONJ was achieved was statistically better in the oral BP group than in the IV BP group after 6 months of treatment (P<0.001). The results showed that >90% of patients treated with oral BPs could be cured. However, 50% of patients treated with IV BPs did not show an improvement. Additional research is needed to further increase the therapeutic efficacy for the resolution of BRONJ.
Collapse
Affiliation(s)
- T Shintani
- Centre of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, Japan.
| | - Y Hayashido
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - H Mukasa
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - E Akagi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - M Hoshino
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Ishida
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - T Hamana
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - K Okamoto
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - T Kanda
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - K Koizumi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Yoshioka
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - R Tani
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - S Toratani
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - T Okamoto
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
35
|
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-9. [PMID: 25867264 PMCID: PMC4453666 DOI: 10.1038/bjc.2015.101] [Citation(s) in RCA: 500] [Impact Index Per Article: 55.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 02/19/2015] [Accepted: 02/19/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND PD-L1 (programmed cell death 1 ligand 1) on tumour cells suppresses host immunity through binding to its receptor PD-1 on lymphocytes, and promotes peritoneal dissemination in mouse models of ovarian cancer. However, how PD-L1 expression is regulated in ovarian cancer microenvironment remains unclear. METHODS The number of CD8-positive lymphocytes and PD-L1 expression in tumour cells was assessed in ovarian cancer clinical samples. PD-L1 expression and tumour progression in mouse models under conditions of altering IFN-γ signals was assessed. RESULTS The number of CD8-positive cells in cancer stroma was very high in peritoneally disseminated tumours, and was strongly correlated to PD-L1 expression on the tumour cells (P<0.001). In mouse models, depleting IFNGR1 (interferon-γ receptor 1) resulted in lower level of PD-L1 expression in tumour cells, increased the number of tumour-infiltrating CD8-positive lymphocytes, inhibition of peritoneal disseminated tumour growth and longer survival (P=0.02). The injection of IFN-γ into subcutaneous tumours induced PD-L1 expression and promoted tumour growth, and PD-L1 depletion completely abrogated tumour growth caused by IFN-γ injection (P=0.01). CONCLUSIONS Interferon-γ secreted by CD8-positive lymphocytes upregulates PD-L1 on ovarian cancer cells and promotes tumour growth. The lymphocyte infiltration and the IFN-γ status may be the key to effective anti-PD-1 or anti-PD-L1 therapy in ovarian cancer.
Collapse
Affiliation(s)
- K Abiko
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - N Matsumura
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - J Hamanishi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - N Horikawa
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - R Murakami
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - K Yamaguchi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Y Yoshioka
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - T Baba
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - I Konishi
- Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - M Mandai
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kinki University, 377-2 Onohigashi, Osakasayama, Osaka 589-0014, Japan
| |
Collapse
|
36
|
Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Hayashi M, Tsuboi S, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study. Rheumatology (Oxford) 2014; 54:854-9. [DOI: 10.1093/rheumatology/keu418] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Indexed: 11/13/2022] Open
|
37
|
Seo Y, Yoshizaki K, Hayashi K, Tamari K, Isohashi F, Suzuki O, Yoshioka Y, Ogawa K. Systematic Linear-Quadratic Analysis for Radiosensitization In Vitro: Implications for Hypofractionated Radiation Therapy in the Combined Modality Approaches. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Isohashi F, Yoshioka Y, Mabuchi S, Seo Y, Suzuki O, Sumida I, Otani Y, Kimura T, Ogawa K. Dose-Volume Analysis of Predictors for Acute Hematologic Toxicity in Patients With Cervical Cancer Treated With Postoperative Pelvic Radiation Therapy and Concurrent Nedaplatin-Based Chemotherapy. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
Ota S, Sumida I, Yoshioka Y, Inoue S, Ogawa K. Feasible Strategy for Reduction of Individual Human Failures in External Radiation Therapy Workflow. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.2165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
40
|
Nishio S, Mikami Y, Otsuki T, Yaegashi N, Satoh T, Yoshikawa H, Saitoh M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, Yoshioka Y, Konishi I, Kojima A, Takehara K, Kaneki E, Kobayashi H, Ushijima K, Kamura T. Recurrence Patterns of Gastric-Type Adenocarcinoma (Gas) of the Uterine Cervix: a Subset Analysis of the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group (Jcog) Gas Multicenter Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Kojima T, Takahashi N, Funahashi K, Asai S, Hirabara S, Hanabayashi M, Yoshioka Y, Yabe Y, Ishiguro N. SAT0063 Importance of Concomitant Methotrexate with TOCILIZUMAB and Assessment of Structual Damage for Achieving Better Clinical Outcomes for Rheumatoid Arthritis Patients with High Disease Activity: an Observational Cohort Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Hirabara S, Kojima T, Takahashi N, Hirano Y, Yabe Y, Kaneko A, Funahashi K, Hanabayashi M, Asai S, Yoshioka Y, Ishiguro N. SAT0251 Three Biological DMARDS of Different Classes Exhibit Equivalent Efficacy in Rheumatoid Arthritis Patients with Inadequate Response to Anti-TNF Monoclonal Antibodies. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Hanabayashi M, Kojima T, Takahashi N, Kida D, Funahashi K, Hirabara S, Asai S, Yoshioka Y, Ishiguro N. SAT0237 The Clinical Efficacy and Safety of Abatacept for Rheumatoid Arthritis from Japanese Multi-Center Registry: 2-Year Outcomes. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Funahashi K, Kojima T, Takahashi N, Hanabayashi M, Hirabara S, Asai S, Yoshioka Y, Yabe Y, Ishiguro N. FRI0332 Considering the Maintenance Treatment with TOCILIZUMAB for Rheumatoid Arthritis, We HAD Better Treat in Combination with Mtx. the Report of 2Years Multi-Center Clinical Practice. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Yamaguchi K, Amano Y, Matsumura N, Mandai M, Abiko K, Hamanishi J, Yoshioka Y, Baba T, Konishi I. HNF1B contributes to resistance to oxidative stress through modification of metabolism in ovarian clear cell carcinoma. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.232] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Asai S, Kojima T, Oguchi T, Takahashi N, Funahashi K, Hanabayashi M, Hirabara S, Yoshioka Y, Ishiguro N. OP0069 Concomitant Methotrexate Affect the Incidence of Large Joint Replacement Surgery in the Rheumatoid Arthritis Patients Treated with Etanercept. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Hirano Y, Kanayama Y, Yoshioka Y, Kanda H, Kaneko A, Kojima T, Ishiguro N. AB0478 Influences of Disease Activity at Initiation of Iguratimod, A Small-Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis: A Multicenter Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Yanai H, Yoshioka Y, Yoshida H, Nakao Y, Plessis A, Yamaguchi M. Drosophila myeloid leukemia factor acts with DREF to activate the JNK signaling pathway. Oncogenesis 2014; 3:e98. [PMID: 24752236 PMCID: PMC4007195 DOI: 10.1038/oncsis.2014.13] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 02/27/2014] [Accepted: 03/03/2014] [Indexed: 12/29/2022] Open
Abstract
Drosophila myelodysplasia/myeloid leukemia factor (dMLF), a homolog of human MLF1, oncogene was first identified by yeast two-hybrid screen using the DNA replication-related element-binding factor (DREF) as bait. DREF is a transcription factor that regulates proliferation-related genes in Drosophila. It is known that overexpression of dMLF in the wing imaginal discs through the engrailed-GAL4 driver causes an atrophied wing phenotype associated with the induction of apoptosis. However, the precise mechanisms involved have yet to be clarified. Here, we found the atrophied phenotype to be suppressed by loss-of-function mutation of Drosophila Jun N-terminal kinase (JNK), basket (bsk). Overexpression of dMLF induced ectopic JNK activation in the wing disc monitored with the puckered-lacZ reporter line, resulting in induction of apoptosis. The DREF-binding consensus DRE sequence could be shown to exist in the bsk promoter. Chromatin immunoprecipitation assays in S2 cells with anti-dMLF IgG and quantitative real-time PCR revealed that dMLF binds specifically to the bsk promoter region containing the DRE sequence. Furthermore, using a transient luciferase expression assay, we provide evidence that knockdown of dMLF reduced bsk gene promoter activity in S2 cells. Finally, we show that dMLF interacts with DREF in vivo. Altogether, these data indicate that dMLF acts with DREF to stimulate the bsk promoter and consequently activates the JNK pathway to promote apoptosis.
Collapse
Affiliation(s)
- H Yanai
- Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan
| | - Y Yoshioka
- Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan
| | - H Yoshida
- 1] Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan [2] Insect Biomedical Research Center, Kyoto Institute of Technology, Kyoto, Japan
| | - Y Nakao
- Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan
| | - A Plessis
- Institut Jacques Monod, CNRS, UMR 7592, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - M Yamaguchi
- 1] Department of Applied Biology, Kyoto Institute of Technology, Kyoto, Japan [2] Insect Biomedical Research Center, Kyoto Institute of Technology, Kyoto, Japan
| |
Collapse
|
49
|
Yoshioka Y, Suzuki O, Nakai Y, Uemura M, Nonomura N, Ogawa K. OC-0318: High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: Seven-year results. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30423-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Yamashita T, Kamada H, Kanasaki S, Maeda Y, Nagano K, Abe Y, Inoue M, Yoshioka Y, Tsutsumi Y, Katayama S, Inoue M, Tsunoda S. Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. Pharmazie 2013; 68:969-973. [PMID: 24400444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Detection of drug-target proteins and biomarkers that are expressed in cancer tissue has significant potential for both diagnosis and treatment of cancer. However, current immuno-histochemical and cytogenetic analyses of biopsy specimens for pre-operational diagnosis are highly invasive and often difficult to apply to lung cancer patients. The purpose of this study was to evaluate the possible utility of determining epidermal growth factor receptor (EGFR) expression on exosomal membranes using a targeted ELISA with an anti-CD81 antibody as a capture antibody for lung cancer diagnosis. While soluble EGFR (sEGFR) levels in plasma were not remarkably different between lung cancer patients and normal controls, significantly higher exosomal EGFR expression levels were observed in 5/9 cancer cases compared to normal controls. These results suggest that measurement of exosomal protein levels could be useful for in vitro diagnosis, and that exosomal EGFR is a possible biomarker for characterization of lung cancer.
Collapse
Affiliation(s)
- T Yamashita
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - H Kamada
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - S Kanasaki
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - Y Maeda
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - K Nagano
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - Y Abe
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - M Inoue
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - Y Yoshioka
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - Y Tsutsumi
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - S Katayama
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| | - M Inoue
- Department of Biochemistry, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - S Tsunoda
- Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, Osaka, Japan
| |
Collapse
|